期刊文献+

血清多肽谱对高级别浆液性卵巢癌诊断价值分析 被引量:4

Serum protein profiling application value in high-grade-serous ovarian cancer diagnosis
原文传递
导出
摘要 目的寻找高级别浆液性卵巢癌相关的血清标志,并评价其诊断价值。方法收集2006-07-17-2011-03-30浙江省肿瘤医院卵巢癌血清样本165例,均经病理确诊。采用纳米磁珠结合基质辅助激光解析离子化飞行时间质谱(MALDI-TOF-MS)技术,检测95例高级别浆液性卵巢癌患者、34例其他上皮性卵巢癌患者、36例卵巢良性肿瘤患者和70名健康志愿者血清样本,并获得血清多肽谱。采用Biomarker Wizard软件分析所获得的多肽谱找出差异蛋白,进一步采用SPSS 12.0中ROC曲线分析差异蛋白,评价其诊断灵敏度和特异性。结果通过34例高级别浆液性卵巢癌患者和34名年龄匹配的健康人群血清多肽谱比较筛选出8个差异峰,P<0.000 1。进一步扩大样本量,经分析ROC曲线面积>0.9的有2 742、8 568和8 692m/z 3个差异峰;当差异峰2 742m/z取临界值24.31时,其诊断敏感性和特异性分别为90%和84.2%,其中早期卵巢癌诊断敏感性为82.35%。早期(Ⅰ、Ⅱ)与晚期(Ⅲ、Ⅳ)高级别浆液性卵巢癌比较有3 163、4 180和4 288m/z 3个差异峰,P<0.01,其ROC曲线面积均>0.7;其中3 163m/z鉴别早晚期高级别浆液性卵巢癌敏感性和特异性分别为52.9%和88.5%。高级别浆液性卵巢癌患者与其他上皮性卵巢癌患者比较无明显差异峰。高级别浆液性卵巢癌患者和卵巢良性肿瘤患者比较有13 745、15 930和28 111m/z 3个差异峰,P<0.01,ROC曲线面积>0.7的差异峰有15 930和28 111 m/z;其中15 930 m/z的鉴别诊断敏感性和特异性分别达到52.6%和80.6%。结论 2 742m/z差异蛋白对于早期高级别卵巢癌具有较高的诊断价值,3 163m/z在早期和晚期高级别浆液性卵巢癌患者的鉴别诊断中有一定价值,15 930m/z对于高级别浆液性卵巢癌和良性卵巢肿瘤鉴别诊断有一定的价值。 OBJECTIVE To analyze the serum proteomic patterns in the high-grade-serous ovarian cancer patients using magnetic bead with MALDI-TOF,and evaluate its clinic significance.METHODS Collection of 165 ovarian cancer serum samples from 2006-07-17 to 2011-03-30 in Zhejiang cancer hospital,all diagnosed by pathology.WCX magnetic bead and MALDI-TOF-MS were used to detect the serum proteome patterns of 129 patients with ovarian carcinomas,36 patients with benign ovarian disease and 70 healthy women.Biomarker Wizard software was used to detect significantly different protein peaks between ovarian cancer and controls.The SPSS 12 ROC curve analysis of differential protein was used to evaluate its diagnostic sensitivity and specificity.RESULTS Eight protein peaks were significantly different between ovarian carcinomas and controls,P〈0.000 1.Further expanding the sample size,the ROC curve area of 2742,8568 and 8692m/z exceeded to 0.9.When different peak 2742m/z cutoff value was 24.31,the diagnostic sensitivity and specificity were 90% and 84.2%,the sensitivity to early diagnosis of ovarian cancer was 82.35%.Three protein peaks were significantly different between early and late high-grade-serous ovarian cancer,P〈0.01.Their ROC curve area are greater than 0.7.The differential diagnostic sensitivity and specificity of 3163m/z were respectively 52.9% and88.5%.High-grade-serous ovarian cancer patients and other patients with epithelial ovarian cancer showed no significant different peaks.Three protein peaks were significantly different between high-grade-serous ovarian cancer and ovarian benign tumor patients,P0.01.The ROC curve area of 15 930 and 28 111m/z exceeded 0.7.The differential diagnostic sensitivity and specificity of 15 930m/z were respectively 52.6%and 80.6%.CONCLUSION Protein 2 742m/z has relatively high value for early diagnos of high-grade-serous ovarian cancer,3 163m/z has a certain value in the differential diagnosis of early and late high-grade-serous ovarian cancer patients.15 930m/z has a certain value for
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第20期1633-1636,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 浙江省自然科学基金(Y2100593 Y2080586) 国家自然科学基金青年科学基金(81202053)
关键词 卵巢肿瘤 飞行时间质谱 纳米磁珠 血清多肽谱 诊断 ovarian neoplasms MALDI-TOF-MS magnetic bead serum protein profiling diagnosis
  • 相关文献

参考文献15

  • 1Hamidou Z, Causeret S, Dabakuyo TS, et al. Population-based study of ovarian cancer in C6te d' Or: prognostic factors and trends in relative survival rates over the last 20 years [J]. BMC Cancer, 2010, 101622. 被引量:1
  • 2Vaughan S, Coward JI, Bast RC Jr, et al, Rethinking ovarian cancer: recommendations for improving outcomes [J].Nat Rev Cancer, 2011, 11(10) :719-725. 被引量:1
  • 3Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review [J]. Semin Surg Oncol, 2000, 19(1) :11-19. 被引量:1
  • 4Cho K, Shih IM. Ovarian cancer [J]. Ann Rev Pathol, 2009, 4 : 287-313. 被引量:1
  • 5Prat J. New insights into ovarian cancer pathology [J]. Ann Oncol, 2012, 23(Suppl 10) : x111-117. 被引量:1
  • 6Tessitore A, Gaggiano A, Cicciarelli G, et al. Serum biomark- ers identification by mass spectrometry in high-mortality tumors [J]. Int J Proteomies, 2013, 2013: 125858. 被引量:1
  • 7Wegdam W, Moerland PD, Meijer D, et al. A critical assess- ment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass [J]. Proteome Sci, 2012, 10(1) :45-54. 被引量:1
  • 8Jia L, Zhang H, Qu X, et al. Proteomic analysis reflects differ- ent histologic subtypes of epithelial ovarian cancer [J]. Med Hy- potheses, 2012,78(3) :407-409. 被引量:1
  • 9Wang J, Zhang X, Ge X, et al. Proteomic studies of early-stage and advanced ovarian cancer patients [J]. Gynecol Oncol, 2008, 111(1) : 111-119. 被引量:1
  • 10赵晋,汤泓,李红霞.卵巢癌患者术前、术后、复发及化疗过程中血清蛋白质差异表达研究[J].中国实验诊断学,2012,16(6):1038-1040. 被引量:6

二级参考文献27

  • 1邱继刚,樊嘉,刘银坤,周俭,邱双健,代智,康晓楠,黄成,杨芃原,汤钊猷.肝细胞癌门静脉癌栓相关血清小分子量蛋白质标志物的筛选[J].中华肝脏病杂志,2007,15(7):498-502. 被引量:2
  • 2Ozols RF,Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer[J]. Cancer Cell, 2004,5 (1) : 19-24. 被引量:1
  • 3Hellstrom I, Raycraft J, Hayden-ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J].Cancer Res,2003,63(?) :3695- 3700. 被引量:1
  • 4Kamei M,Yamashita SI,Tokuishi K,et al. HFA expression can be asso ciated with lymph node metastases and disease-free survival in breast cancer[J]. Anticancer Research, 2010,30 (11) :4779- 4783. 被引量:1
  • 5Coppola D,Szabo M,Boulware D,et al. Correlation of osteopontin pro- tein expression and pathological stage across a wide variety of tumor histologies[J]. Clin Cancer Res,2004,10(1) :184-190. 被引量:1
  • 6Drapkin R,Horsten HH, LinY,et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by se- rous and endometrioid ovarian carcinomas[J].Cancer Res,2005, 65(3):2162-2169. 被引量:1
  • 7Pan HW,Ou YH,Peng SY, et al. Overexpression of osteopontin is associated with intrahepatie metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma [J]. Cancer, 2003,98 ( 1 ) : 119. 被引量:1
  • 8Moore RG, Brown Aid, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncology,2008,108(2):402-408. 被引量:1
  • 9Posadas EM,Davidson B,Kohn EC. Proteomics and ovarian canc- er:implications for diagnosis and treatment:a critical review the recent literature[J] CurrOp in Oncol, 2004,16 (5) : 478. 被引量:1
  • 10Da EleneM, Katerina O, John M, et al. Mass Spectrometry: Un- covering the Cancer Proteome for Diagnostics[J]. Adv Cancer Res,2006,96(2) :23. 被引量:1

共引文献29

同被引文献31

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部